PBPK Model - DDI Confidential 2 May 2025

13.Appendix 4.

Study Design and Results of DDI Simulations

Table A2. Study design, observed and predicted AUC and C_{max} ratios using Simcyp Simulator V19R1To

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted	Pred /Obse	
1 (4.11.2002	zvaa,		2 4234 400 2 530	2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
1	(1)	CYP3A4/5	Alfentanil 15 μg/kg single iv (3 hr after fluconazole)	Fluconazole, 100 mg (single oral)	-	1.2	-	1.27	-	1.06
2	(1)	CYP3A4/5	Alfentanil 40 μg/kg single oral (3 hr after fluconazole)	Fluconazole, 100 mg (single oral)	1.16	2	1.42	1.68	1.22	0.84
3	(1)	CYP3A4/5	Alfentanil 15 μg/kg single iv (3 hr after fluconazole)	Fluconazole, 200 mg (single oral)	-	1.6	-	1.52	-	0.95
4	(1)	CYP3A4/5	Alfentanil 40 μg/kg single oral (3 hr after fluconazole)	Fluconazole, 200 mg (single oral)	1.53	3.1	1.76	2.37	1.15	0.74
5	(1)	CYP3A4/5	Alfentanil 15 μg/kg single iv (3 hr after fluconazole)	Fluconazole, 400 mg (single oral)	-	2.2	-	1.95	-	0.89
6	(1)	CYP3A4/5	Alfentanil 40 μg/kg single oral (3 hr after fluconazole)	Fluconazole, 400 mg (single oral)	1.72	5.5	2.25	3.66	1.31	0.67

Number	Study	СУР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted		licted erved
	~~,		~~~~~~~~~~		C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
7	(2)	CYP3A4/5	unlabelled d0-Alfentanil 0.5 mg iv on day 4 (assuming at 7:00 AM)	Ketoconazole, 400 mg (oral) for 3 days at bedtime (3 doses, assuming at 11:30 PM)	-	4.8	-	3.93	-	0.82
8	(2)	CYP3A4/5	deuterium-labelled d3- Alfentanil 1 mg oral on day 4 (assuming at 10:00 AM)	Ketoconazole, 400 mg (oral) for 3 days at bedtime (3 doses, assuming at 11:30 PM)	2.8	9.2	3.47	7.58	1.24	0.82
9	(2)	CYP3A4/5	unlabelled d0-Alfentanil 0.5 mg iv on day 5 (assuming at 7:00 AM)	Ketoconazole, 400 mg (oral) for 4 days at bedtime (4 doses, assuming at 11:30 PM)	-	5.0	-	3.95	-	0.79
10	(2)	CYP3A4/5	deuterium-labelled d3- Alfentanil 1 mg oral on day 5 (assuming at 7:00 AM)	Ketoconazole, 400 mg (oral) for 4 days at bedtime (4 doses, assuming at 11:30 PM)	5.07	12.0	3.93	10.14	0.78	0.85
11	(3)	CYP3A4/5	Alprazolam, 1 mg SD (day 3), (1 h after 5th Ketoconazole dose)	Ketoconazole, 200 mg BID for 4 days (8 doses)	1.1	3.98	1.1	2.75	1.0	0.69
12	(4)	CYP3A4/5	Alprazolam, 0.5 mg SD (day 4)	Ketoconazole, 200 mg BID for 6 days (12 doses)	1.18	2.91	1.09	3.07	0.92	1.05
13	(4)	CYP3A4/5	Alprazolam, 0.5 mg SD (day 4)	Ketoconazole, 200 mg QD for 6 days (6 doses)	1.18	2.7	1.1	2.71	0.93	1.00
14	(5)	CYP3A4/5	Alprazolam, 0.8 mg SD (day 8)	Erythromycin, 400 mg TID for 10 days (30 doses)	1.18	2.47	1.07	2.49	0.91	1.01

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted	Pred /Obse	
					C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
15	(6)	CYP3A4/5	Alprazolam, 1 mg SD (day 2) RTV summary (At 8.30am)	Ritonavir, 200 mg 4 doses over 3 days at 4pm d1, 7.30am and 4.30pm D2, 9am D3	1.04	2.48	1.1	3.64	1.06	1.47
16	(7)	CYP3A4/5	Alprazolam, 1 mg SD on day 22	Fluoxetine, 20 mg QD for 24 days	1.09	1.32	1.02	1.22	0.94	0.92
17	(8)	CYP3A4/5	Alprazolam, 0.5 mg TID for 7 days and morning dose on day 8	Cimetidine, 200 mg TID with 400mg at night for 9 days	1.82	1.64	1.06	1.08	0.58	0.66
18	(9)	CYP3A4/5	Aprepitant, 125 mg SD day 5	Ketoconazole, 400 mg QD for 10 days	1.52	4.78	1.47	3.93	0.97	0.82
19	(10)	CYP3A4/5	Atazanavir, 400 mg QD for 13 days	Ketoconazole, 200 mg QD days 7 – 13	0.98	1.1	1.19	1.23	1.21	1.12
20	(11)	CYP3A4/5	Atazanavir, 400 mg QD for 10 days	Clarithromycin, 500mg BID days 7 – 10	1.06	1.28	1.09	1.1	1.02	0.86
21	(11)	CYP3A4/5	Clarithromycin, 500 mg BID days 7 – 10	Atazanavir, 400 mg QD for 10 days	1.5	1.94	1.37	1.59	0.91	0.82
22	(12)	CYP3A4/5	Clarithromycin, 500 mg BID for 4 days (8 doses)	Ritonavir, 200 mg TID for 4 days (12 doses)	1.54	1.86	1.76	2.95	1.1	1.52
23	(13)	CYP3A4/5	Dexamethasone, 4.5 mg Day 4 at 9am	Itraconazole, Capsule 200 mg QD at 7.30 am on day 1-3 and 8am on day 4	1.58	3.69	1.59	3.59	1.01	0.97

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	licted		licted erved
1 (umoci	Stady		Substrate 2 sse	Timiotor 2 dae	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
24	(14)	CYP3A4/5	Dexamethasone, 20 mg QD Day 1, 8 mg Day 2-5	Aprepitant, 125 mg QD day 1 (30 min before Dex), 80 mg QD day 2-5	1.52	2.2	1.15	1.34	0.76	0.61
25	(15)	CYP3A4/5	Dexamethasone, 20 mg QD Day 1, 8 mg Day 2-5	Aprepitant, 375 mg Day 1, 250 mg QD Day 2-5	1.82	4.1	1.41	2.1	0.77	0.51
26	(15)	CYP3A4/5	Dexamethasone, 12 mg QD Day 1, 4 mg Day 2-5	Aprepitant, 125 mg QD day 1, 80 mg QD Day 2-5	0.79	1.03	1.17	1.38	1.48	1.34
27	(15)	CYP3A4/5	Dexamethasone, 20 mg QD Day 1, 8 mg Day 2-5	Aprepitant, 40 mg QD Day 1, 25 mg QD Day 2-5	1.1	1.21	1.05	1.09	0.95	0.90
28	(16)	CYP3A4/5	Ibrutinib, 120 mg on Day 4 at 10 am	Ketoconazole, 400 mg QD Days 1-6 at 9 am	28.6	26.2	21.1	29.8	0.74	1.14
29	(17)	CYP3A4/5	Ibrutinib, 140 mg on Day 3 at 9 am (low fat fed)	Itraconazole, 200 mg BID Day 1 (8 am and 8 pm) and QD Days 2-3 (8 am)	8.8	10.2	10.2	14.1	1.16	1.38
30	(18)	CYP3A4/5	Midazolam, 7.5 mg SD (1 h after Fluconazole)	Fluconazole, 400 mg SD	2.3	3.73	1.91	3.05	0.83	0.82
31	(19)	CYP3A4/5	Midazolam, 7.5 mg SD (day 4)	Itraconazole, 200 mg QD for 4 days (8 doses)	3.41	10.77	2.82	9.97	0.83	0.93
32	(20)	CYP3A4/5	Midazolam, 15 mg SD (day 5)	Clarithromycin, 250 mg BID for 5 days (10 doses)	2.44	3.57	2.07	4.13	0.85	1.16

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted	Pred /Obse	icted erved
1 (4111002	Staay		2 42301 410 2 000		C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
33	(21)	CYP3A4/5	Midazolam, 15 mg SD (day 2), (1 h after 4th Diltiazem dose)	Diltiazem, 60 mg TID for 2 days (5 doses)	2.05	3.75	1.55	2.03	0.76	0.54
34	(21)	CYP3A4/5	Midazolam, 15 mg SD (day 2), (1 h after 4th Verapamil dose)	Verapamil, 80 mg TID for 2 days (5 doses)	1.97	2.92	2.12	3.46	1.07	1.19
35	(22)	CYP3A4/5	Midazolam, 6 mg SD (12 h after 1st Ketoconazole dose)	Ketoconazole, 200 mg BID for 2 days (3 doses)	4.24	16.0	3.56	12.56	0.84	0.79
36	(22)	CYP3A4/5	Midazolam, 2 mg IV SD (12 h after 1st Ketoconazole dose)	Ketoconazole, 200 mg BID for 2 days (3 doses)	-	5.1	-	4.67	-	0.92
37	(19)	CYP3A4/5	Midazolam, 7.5 mg SD (day 4)	Ketoconazole, 400 mg QD for 4 days (4 doses)	4.09	15.9	3.78	12.5	0.92	0.79
38	(23)	CYP3A4/5	Midazolam, 2 mg SD (day 5)	Ketoconazole, 400 mg QD for 5 days (5 doses)	5.42	13.96	3.76	12.12	0.69	0.87
39	(24)	CYP3A4/5	Midazolam, 2 mg SD oral coadministered with Aprepitant	Aprepitant, 250 mg SD	1.06	1.63	1.48	1.55	1.40	0.96
40	(24)	CYP3A4/5	Midazolam, 2 mg SD oral Aprepitant Day 8	Aprepitant, 250 mg SD Day 1	0.8	0.69	1.15	1.21	1.44	1.75
41	(25)	CYP3A4/5	Midazolam, 2 mg SD day 1 (1hr after Aprepitant)	Aprepitant, 125 mg day 1, 80 mg QD days 2-5	1.46	2.27	1.39	1.45	0.96	0.64

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted	Pred /Obse	
1 (dimber	Study		Substruce 2000	Timbles 2000	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
42	(25)	CYP3A4/5	Midazolam, 2 mg SD day 1 (1hr after Aprepitant) Day 5	Aprepitant, 125 mg day 1, 80 mg QD days 2-5	1.94	3.3	1.61	1.99	0.83	0.60
43	(26)	CYP3A4/5	Midazolam, Midazolam 1.96 mg iv SD, 1hr after Aprepitant	Aprepitant, 125 mg SD	-	1.47	-	1.03	-	0.7
44	(27)	CYP3A4/5	Midazolam, Midazolam 2 mg iv SD day 4	Aprepitant, 125 mg day 1, 80 mg QD days 2-3	0.8	1.25	1.01	1.26	1.26	0.99
45	(27)	CYP3A4/5	Midazolam, Midazolam 2 mg iv SD day 8	Aprepitant, 125 mg day 1, 80 mg QD days 2-3	1.08	0.81	1.00	1.09	0.93	1.35
46	(28)	CYP3A4/5	Midazolam, 15 mg SD (Day 2) (30min after cimetidine)	Cimetidine, 400 mg BID (3 doses)	-	1.35	-	1.37	-	1.01
47	(29)	CYP3A4/5	Midazolam, 15 mg SD (2hrs after cimetidine)	Cimetidine, 400 mg SD	1.37	1.37	1.21	1.24	0.88	0.91
48	(30)	CYP3A4/5	Midazolam, 15 mg SD (Day 2) (2.5hr after cimetidine)	Cimetidine, 200 mg TID with 400 mg at night on day 1. 200 mg on day 2	2.38	2.02	1.09	1.1	0.46	0.54
49	(31)	CYP3A4/5	Midazolam, 15 mg on day	Erythromycin, 500 mg TID 7 days	2.7	4.42	2.75	7.59	1.02	2.72
50	(32)	CYP3A4/5	Midazolam, 10 mg SD on day 12 (1h after fluvoxamine)	Fluvoxamine, 50 mg BID days 1-6, 100 mg (73.3 mg free base) BID days 7-12	1.38	1.39	1.25	1.37	0.91	0.99

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted		licted erved
1 (dimber	Stady		Substract 2000	Timiotor 2 dae	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
51	(33)	CYP3A4/5	Midazolam, 7.5 mg SD day 4	Itraconazole, 100 mg QD for 4 days	2.56	5.47	2.38	4.99	0.93	0.91
52	(34)	CYP3A4/5	Midazolam, 7.5 mg SD day 4	Itraconazole, 200 mg QD for 4 days	2.91	5.16	2.82	7.15	0.97	1.39
53	(23)	CYP3A4/5	Midazolam, 2 mg SD	Ketoconazole, 400 mg SD	5.0	10.3	3.74	11.9	0.75	1.16
54	(35)	CYP3A4/5	Midazolam, 2 mg SD	Ketoconazole, 200 mg SD 2 hrs before MDZ	2.7	5.0	3.4	6.5	1.26	1.30
55	(36)	CYP3A4/5	Midazolam, 75 ug SD Day 3	Ketoconazole, 200 mg BID 2 days	3.7	6.5	2.6	5.2	0.70	0.80
56	(37)	CYP3A4/5	Midazolam, 3 mg day 4	Ritonavir, 30 mg for 5 days	-	3.89	-	4.59	-	1.18
57	(37)	CYP3A4/5	Midazolam, 3 mg day 4	Ritonavir, 100 mg for 5 days	-	6.51	-	6.98	-	1.07
58	(37)	CYP3A4/5	Midazolam, 3 mg day 4	Ritonavir, 300 mg for 5 days	-	9.01	-	7.45	-	0.83
59	(38)	CYP3A4/5	Midazolam, 1 mg IV Dose	Ritonavir, 200 mg for 11 days	-	4.9	-	4.7	-	0.98
60	(39)	CYP3A4/5	Midazolam, 3 mg SD on Day 2 (8 am)	Ritonavir, 100 mg at 6 pm day 1 and 7.30 am and 6 pm Day 2 (2 doses)	3.96	26.41	3.36	17.29	0.85	0.65
61	(40)	CYP3A4/5	Midazolam, 0.1 mg SD	Ritonavir, 100 mg BID	3.26	14.7	2.83	11.57	0.87	0.79
62	(41)	CYP3A4/5	Midazolam, 5 mg SD	Ritonavir, 100 mg BID for 14 days	4.03	23.9	3.44	18.9	0.85	0.79

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted	Pred /Obse	
			~~~~~~~~~~		C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
63	(42)	CYP3A4/5	Midazolam, 2 mg on Day 16	Ritonavir, 200 mg TID day 1, 300 mg Day 2-7, 400 mg BID days 8-15	-	10.5	-	19.05	-	1.81
64	(43)	CYP3A4/5	Nifedipine, 10 mg TID for 4 days, 1 dose day 5.	Cimetidine, 800 mg QD for 5 days	2.3	2.0	1.39	1.61	0.60	0.81
65	(44)	CYP3A4/5	Nifedipine, 10 mg QID for 6 days, 1 dose day 7.	Cimetidine, 200 mg TID with 400 mg at night for 7 days	2.02	1.6	1.12	1.22	0.55	0.76
66	(45)	CYP3A4/5	Nifedipine, 20 mg SD day 2 (1hr after first cimetidine dose)	Cimetidine, 200 mg TID with 400 mg at night for 3 days	-	1.31	-	1.22	-	0.93
67	(46)	CYP3A4/5	Nifedipine, 20 mg SD day 7	Cimetidine, 300 mg QID for 7 days	1.4	1.52	1.52	1.31	0.85	0.86
68	(47)	CYP3A4/5	Nifedipine, 20 mg SD day 5 (1hr after cimetidine)	Cimetidine, 800 mg QD for 5 days	1.65	1.77	1.5	1.67	0.91	0.94
69	(48)	CYP3A4/5	Nifedipine, 20 mg SD	Diltiazem, 60 mg 1 hour before nifedipine	-	1.33	-	1.18	-	0.89
70	(48)	CYP3A4/5	Nifedipine, 20 mg SD	Diltiazem, 60 mg TDS for 3 days and a final dose 1 hour before nifedipine	-	2.4	-	2.57	-	1.07
71	(48)	CYP3A4/5	Nifedipine, 20 mg SD	Diltiazem, 60 mg TDS for 6 days and a final dose 1 hour before nifedipine	-	2.96	-	2.73	-	0.92

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted	Pred /Obse	
1,4411	zvaa,		2 <b>4</b> 000 2 000	2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
72	(49)	CYP3A4/5	Nifedipine, 20 mg SD	Diltiazem, 30 mg TDS for 3 days and a final dose 1 hour before nifedipine	2.01	2.2	1.39	1.79	0.69	0.82
73	(49)	CYP3A4/5	Nifedipine, 20 mg SD	Diltiazem, 90 mg TDS for 3 days and a final dose 1 hour before nifedipine	1.7	3.1	1.87	3.23	1.1	1.04
74	(50)	CYP3A4/5	Quinidine, 332 mg SD (day 4)	Verapamil, 80 mg TID for 4 days (12 doses)	-	1.47	-	2.45	-	1.67
75	(50)	CYP3A4/5	Quinidine, 332 mg SD (day 4)	Verapamil, 120 mg TID for 4 days (12 doses)	-	1.5	-	2.89	-	1.93
76	(51)	CYP3A4/5	Quinidine, 200 mg SD (day 3), (1.5 h after last Diltiazem dose)	Diltiazem, 90 mg BID for 3 days (5 doses)	1.09	1.51	1.18	1.66	1.08	1.10
77	(52)	CYP3A4/5	Quinidine, 330 mg (free base) SD on day 6	Cimetidine, 300 mg QID for 7 days	1.2	1.57	1.07	1.15	0.89	0.73
78	(53)	CYP3A4/5	Quinidine, 330 mg (free base) SD on day 4	Cimetidine, 300 mg QID for 3 days, morning dose day 4	1	1.27	1.06	1.09	1.06	0.86
79	(54)	CYP3A4/5	Quinidine, 166 mg free base, single dose, oral	Itraconazole, 100 mg, QD, 7 days, oral	1.32	2.58	1.33	2.23	1.01	0.86
80	(55)	CYP3A4/5	Quinidine, 83 mg free base, single dose, day 4	Itraconazole, 200 mg QD, oral, 4 days	1.59	2.42	1.37	2.84	0.86	1.17
81	(54)	CYP3A4/5	Quinidine, 166 mg free base, single dose, oral	Erythromycin, 250 mg, QID, 7 days, oral	1.39	1.19	1.26	2.45	0.91	2.06

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted		icted erved
1,444	z <b>uu</b> j		2 4234-440-2 330	2	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
82	(56)	CYP3A4/5	Quinidine, 166 mg free base, single dose, oral, day 5	Fluvoxamine, 100 mg, QD, oral, 6 days	1.35	1.41	1.1	1.22	0.81	0.87
83	(57)	CYP3A4/5	Repaglinide, 0.25 mg on day 3 (1 h after Itraconazole)	Itraconazole, 200 mg (1st dose) 100 mg BID for 3 days (7 doses)	1.47	1.42	1.35	1.57	0.92	1.11
84	(58)	CYP3A4/5	Repaglinide, 0.25 mg SD (1h after 2nd Cyclosporine dose)	Cyclosporine, 100 mg BID (2 doses, 8 pm and 8 am)	1.71	2.44	1.53	1.68	0.89	0.69
85	(59)	CYP3A4/5	Repaglinide, 0.25 mg day 5 given 1 hour after clarithromycin	Clarithromycin, 250 mg oral every 12 h for 4 days	1.66	1.4	1.74	2.17	1.05	1.55
86	(58)	CYP3A4/5	Repaglinide, 0.25 mg, 1hr after 2nd dose of cyclosporine	Cyclosporine, 100 mg, BID for 1 day	1.71	2.44	1.53	1.68	0.89	0.69
87	(60)	CYP3A4/5	Rifabutin, 300 mg QD for 14 days	Fluconazole, 200 mg QD for 14 days	1.88	1.82	1.28	1.64	0.68	0.90
88	(61)	CYP3A4/5	Rifabutin, 300 mg QD from day 15	Fluconazole, 200 mg QD for 28 days	1.7	1.8	1.29	1.66	0.76	0.92
89	(60)	CYP3A4/5	Rifabutin, 300 mg QD for 10 days	Ritonavir, 500 mg BD for 10 days	1.5	3.0	1.7	2.62	1.13	0.87
90	(62)	CYP3A4/5	Rifabutin, 300 mg QD for 42 days	Clarithromycin, 500 mg BD from day 15	1.69	1.99	1.43	1.96	0.85	0.98

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted	Pred /Obse	
1 (dimber	Stady		Substrate 2 die	11111101101 2 USC	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
91	(63)	CYP3A4/5	Sildenafil, 50 mg SD (2 h after Clarithromycin dose)	Clarithromycin, 500 mg SD	2.42	2.28	1.46	1.69	0.60	0.74
92	(64)	CYP3A4/5	Sildenafil, 100 mg (day 5), (1 h after 10th Erythromycin dose)	Erythromycin, 500 BID for 5 days (10 doses)	2.09	2.58	2.13	4.35	1.02	1.68
93	(65)	CYP3A4/5	Sildenafil, 100 mg SD (day 6)	Ritonavir, 300 mg BID Day 1 400 mg BID Day 2 500 mg BID Days 3-7 (14 doses)	3.89	9.9	2.8	10.08	0.72	1.02
94	(66)	CYP3A4/5	Sildenafil, 50 mg SD day 3 (2hrs after cimetidine)	Cimetidine, 800 mg QD for 4 days	1.54	1.56	1.36	1.42	0.88	0.91
95	(67)	CYP3A4/5	Simvastatin, 20 mg SD (day 15), (12 h after last Diltiazem dose)	Diltiazem, 120 mg BID for 14 days (28 doses)	3.61	4.82	3.89	5.1	1.08	1.06
96	(68)	CYP3A4/5	Simvastatin, 40 mg QD on Day 4	Amiodarone, 40 mg Days 1-4	1.79	1.76	1.53	1.64	0.86	0.93
97	(69)	CYP3A4/5	Simvastatin, 40 mg SD on Day 2	Erythromycin, 500 mg t.i.d. for 2 days	3.5	6.2	7.46	12.48	2.13	2.01
98	(69)	CYP3A4/5	Simvastatin, 40 mg SD on Day 2	Verapamil, 80mg t.i.d. for 2 days	2.6	4.6	6.5	8.32	2.5	1.81
99	(70)	CYP3A4/5	Simvastatin, 40 mg SD on Day 6. 2hrs before Ketoconazole	Ketoconazole, 400 mg QD for 10 days	7.4	12.6	3.46	8.04	0.47	0.64

Number	Study	СҮР	Substrate Dose	Inhibitor Dose	Obse	rved	Pred	icted		licted erved
1 (umber	Staay		Substrace 2000	Timilator 2000	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio	C _{max} Ratio	AUC Ratio
100	(71)	CYP3A4/5	Simvastatin, 40 mg QD for 8 days	Clarithromycin, 500 mg bid for 8 days	7.1	10	9.68	16.52	1.36	1.65
101	(72)	CYP3A4/5	Triazolam, 0.25 mg (day 2), (1h after 5th Diltiazem dose)	Diltiazem, 60 mg TID for 2 days (5 doses)	1.86	2.83	1.45	2.02	0.78	0.71
102	(73)	CYP3A4/5	Triazolam, 0.25 mg SD (day 4 @3pm)	Fluconazole, 100 mg QD for 4 days (@2pm)	1.25	2.1	1.43	1.88	1.144	0.8952 381
103	(73)	CYP3A4/5	Triazolam, 0.25 mg SD on day 4 (1 hour after Fluconazole)	Fluconazole, 50 mg QD for 4 days (4 doses)	1.47	1.63	1.25	1.51	0.85	0.93
104	(74)	CYP3A4/5	Triazolam, 0.25mg SD on day 4 (1 hour after Fluconazole)	Fluconazole, 100 mg QD for 4 days (4 doses)	1.4	2.05	1.43	1.97	1.02	0.96
105	(74)	CYP3A4/5	Triazolam, 0.25 mg SD on day 4 (1 hour after fluconazole)	Fluconazole, 400 mg Day 1, then 200 mg QD for 3 days (4 doses)	2.33	4.42	1.68	3.01	0.72	0.68
106	(3)	CYP3A4/5	Triazolam, 0.25 mg SD (day 3), (1 h after Ketoconazole dose)	Ketoconazole, 200 mg BID for 4 days (8 doses)	2.08	13.7	2.42	10.9	1.17	0.8
107	(75)	CYP3A4/5	Triazolam, 0.125 mg SD (day 2), (1h after 3rd Clarithromycin dose)	Clarithromycin, 500 mg given at 8 am and 4 pm Day 1 and 8 am and 5 pm on Day 2 (4 doses)	1.97	5.06	1.99	4.18	1.01	0.83
108	(76)	CYP3A4/5	Triazolam, 0.5 mg SD (Day 2)	Cimetidine, 300 mg QID for 2 days	1.39	1.32	1.18	1.22	0.85	0.92